Polaryx Therapeutics, Inc. PLYX Net Operating Loss Carryforwards
Net Operating Loss Carryforwards at other companies
Other financials
Where this comes from
Reported directly by Polaryx Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLossCarryforwards.
The source filing: Polaryx Therapeutics, Inc.’s 10-K, filed March 24, 2026.
- Filed
- Mar 24, 2026, 12:00 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001213900-26-033064
As of December 31, 2025 and 2024, the Company had a federal net operating loss (“NOL”) carryforward of $18.7 million and $15.7 million, respectively. As of December 31, 2025 and 2024, the Company had state NOL carryforwards of $15.7 million and $15.7 million, respectively. Of the $18.7 million of federal NOL carryforwards as of December 31, 2025, $1.1 million begins to expire in 2034 and $17.6 million may be carried forward indefinitely. The state NOL carryforwards begin to expire in 2034.
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Polaryx Therapeutics, Inc.'s net operating loss carryforwards?
- Polaryx Therapeutics, Inc. (PLYX) reported net operating loss carryforwards of $18.7M in Q4 2025.
- What does net operating loss carryforwards mean?
- These are tax assets representing losses that can be used to reduce taxable income in future periods. They provide a potential future tax shield, improving cash flow by lowering future tax payments. Investors monitor these to estimate the duration and magnitude of potential tax savings.
Ask your AI about Polaryx Therapeutics, Inc.'s net operating loss carryforwards.
Connect your AI assistant and compare it to peers, right in your chat.
